
FDA Approves Pertuzumab Biosimilar in HER2+ Breast Cancer
The FDA has approved pertuzumab-qcay, a biosimilar of the reference product Perjeta, in HER2-positive breast cancer, based on a data package that showed no meaningful differences in quality, safety, efficacy, or immunogenicity.
The FDA has approved pertuzumab-qcay (Pebrilzo), a biosimiliar of the reference product Perjeta (pertuzumab), for patients with HER2-positive breast cancer, according to a press release from Biocon Limited.1
The approval comes from a comprehensive package that includes structural and functional analytical characterization, analytical similarity, and comparative clinical pharmacokinetic data. This showed that pertuzumab-qcay was similar to the reference biologic and did not show any meaningful differences in quality, safety, efficacy, or immunogenicity.
In September 2026, the Committee for Medicinal Products for Human Use of the European Medicines Agency gave a positive opinion and recommended the authorization of the biosimilar.2 This was to be given in a 420 mg/14 mL concentration for those with HER2-positive breast cancer across various disease stages.
“The US FDA approval of Pebrilzo, our biosimilar pertuzumab, marks another significant milestone in Biocon’s journey to expand access to high-quality biosimilars. For patients diagnosed with HER2-positive breast cancer, the burden of the disease extends well beyond the physical challenges, often placing considerable financial strain on patients and their families. As our fifth oncology biosimilar to receive US FDA approval, Pembrilzo strengthens our anti-cancer portfolio and advances our commitment to expanding access to high-quality, affordable biologic medicines,” Shreehas Tambe, chief executive officer and managing director of Biocon Limited, said in the press release.
Warnings and precautions for this treatment include left ventricular dysfunction, embryo-fetal toxicity, infusion-related reactions, and hypersensitivity reactions/anaphylaxis. Contraindications were noted for patients with known hypersensitivity to pertuzumab or any of its excipients.
For patients with metastatic breast cancer, the most common adverse effects (AEs) in combination with trastuzumab (Herceptin) and docetaxel were diarrhea, alopecia, neutropenia, nausea, fatigue, rash, and peripheral neuropathy. For those receiving neoadjuvant treatment for breast cancer, the most common AEs were alopecia, diarrhea, nausea, and neutropenia. For those receiving adjuvant treatment for breast cancer, the most common AEs were diarrhea, nausea, alopecia, fatigue, peripheral neuropathy, and vomiting.
References
- Biocon gets U.S. FDA approval for Pebrilzo™ (pertuzumab-qcay) injection, a biosimilar to Perjeta®, expanding its oncology portfolio. News release. Biocon Limited. November 16, 2026. Accessed November 16, 2026. https://tinyurl.com/4f5a9t96
- Biocon’s pertuzumab becomes first biosimilar to secure EMA CHMP approval recommendation under new tailored clinical approach. News release. Biocon Limited. September 21, 2026. Accessed November 16, 2026. https://tinyurl.com/tav7byeh
Related to this article








